Methods and Approaches for Capturing Post-Approval Safety and Efficacy Data on Cell and Gene Therapy Products – Catapult’s regulatory round-up
On the 27th of April 2023, the FDA’s Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT) is hosting a virtual public listening meeting to seek input on methods, approaches, logistics, privacy concerns, and other aspects related to efficacy and safety data collection in the post-approval setting for cell and gene therapies.
Please find further details on this event, including how to register here.
Published on the 3rd of April 2023 in Catapult’s regulatory round-up for March 2023.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (22 décembre 2023). Methods and Approaches for Capturing Post-Approval Safety and Efficacy Data on Cell and Gene Therapy Products – Catapult’s regulatory round-up. ELSIBI. Consulté le 16 janvier 2025 à l’adresse https://doi.org/10.58079/vezd
